Results 81 to 90 of about 3,980 (188)

Antibiotic: a boon to mankind and doom to the environment - an insight on biological and non-biological degradation processes. [PDF]

Front Microbiol
Antony BT, Osborne JW, Benjamin LK.
europepmc   +1 more source

Promising Future of Novel Beta-Lactam Antibiotics Against Bacterial Resistance. [PDF]

Drug Des Devel Ther
Tayeb SM, Alharbi JA, Alattas BB, Alotaibi DM, Althibaiti NM, Alharbi JF, SafirAldeen AE, Alqurashi IR, Wali SM.   +8 more
europepmc   +1 more source

Lorlatinib and Amivantamab: A Paradigm Shift in <i>EGFR</i> and <i>ALK</i> Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making. [PDF]

Oncol Res
Maione P, Palma V, Gridelli C.
europepmc   +1 more source

Chemical Biology [PDF]

, 2014
井上 将彦, 伊藤 達哉, 阿部 肇
core   +2 more sources

Clinical characteristics of the ALK fusion-positive bladder PMP and efficacy of lorlatinib: a two-case report and literature review. [PDF]

Oncologist
Sun M, Ju M, Zhang H, Huang N, Zhang S, Sun M.   +5 more
europepmc   +1 more source

The Madangamines: Synthetic Strategies Toward Architecturally Complex Alkaloids. [PDF]

Mar Drugs
Ríos V, Maulen C, Parra C, Bradshaw B.
europepmc   +1 more source

Lorlatinib in patients with <i>ALK</i>-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study. [PDF]

Future Oncol
Bearz A, Ricciardi S, Vivek Raut N, Dols MC, Chiradoni Thungappa S, Sacco PC, Thurm H, Pavlov D, Toffalorio F, Felip E.   +9 more
europepmc   +1 more source

A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024. [PDF]

PLoS One
Frey C.
europepmc   +1 more source

First case report of lorlatinib in the treatment of ALK-fusion-positive lung adenocarcinoma with ovarian metastasis: Clinicopathological and molecular characterization. [PDF]

Medicine (Baltimore)
Xu T, Hua S, Wang J, Wu M, Qiu X, Hong J, Zhang Y, Shao K, Wang J.   +8 more
europepmc   +1 more source

Structural Diversification of 14-Membered Macrolides by Chemoenzymatic Synthesis. [PDF]

JACS Au
Curtis BJ, Boesger HA, Schmidt JJ, Adrover-Castellano ML, Momin AN, Glasser CA, Sherman DH.   +6 more
europepmc   +1 more source